Details of how to report adverse events are available at the bottom of the page.
For full information on a Roche medicine, please see the relevant Summary of Product Characteristics.
Could TECENTRIQ SC improve efficiency by increasing aseptic capacity and reducing preparation and chair time vs TECENTRIQ IV?
Prof. Alastair Greystoke, senior lecturer and consultant Medical Oncologist, presents how the Newcastle upon Tyne Hospitals NHS Foundation Trust has successfully achieved a much-needed increase in SACT clinic capacity, by transitioning from TECENTRIQ IV to SC.
Watch and learn more about the capacity savings gained by transitioning from IV to SC through this exclusive video from the Roche-funded and organised national lung cancer meeting, LCEF 2024.
This video contains data based on the experience of Ms Ashleigh Hughes, Senior Sister. Roche was not involved in the collection or analysis of the data presented and the data has not been published or peer reviewed.
The IMscin002 trial demonstrated that TECENTRIQ SC was the treatment of choice compared to TECENTRIQ IV, for 8 out of 10 patients.6
Debra was the first patient in the world to receive TECENTRIQ SC. Watch Debra’s story of receiving a lung cancer diagnosis and experiencing subcutaneous administration to find out more about the impact TECENTRIQ SC could have on your patients.
We can support you with the implementation of TECENTRIQ SC in your trust.
Find out more about the resources available to you and how to contact your local Roche representative below.
Pharmacy protocol
The TECENTRIQ SC pharmacy protocol with dosing schedule can support the preparation of your local treatment protocols.
Nurse administration training program
Join our training program developed for nurses to administer TECENTRIQ SC. Contact your local Roche Disease Level Partner or Clinical Nurse Educator for more information.
Ryan Crockford, Nurse, based at Sussex Cancer Centre, University Hopsitals Sussex, demonstrates best practice on how TECENTRIQ SC should be stored and then drawn up in preparation for subcutaneous injection into a patient.
Watch to learn more about best practice for preparing TECENTRIQ SC administration.
This video is intended for healthcare professionals in the United Kingdom. It has been developed by Roche Products Limited to be used as guidance only.
Click on the relevant region below to contact your local disease level partner (DLP) or clinical nurse educator (CNE).
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic UC:
- after prior platinum-containing chemotherapy;
- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5%
Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC. In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumours have a PD-L1 expression ≥ 50% TC or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC.
Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK-positive NSCLC should also have received targeted therapies before receiving Tecentriq.
Tecentriq as monotherapy is indicated for the 1L treatment of adult patients with advanced NSCLC who are
ineligible for platinum-based therapy (platinum ineligible criteria can be found in section 5.1 of the SPC)
Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
Tecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.
Tecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable HCC who have not received prior systemic therapy.
*The median time taken to administer atezolizumab via the subcutaneous route was 7.2 mins (range 3 to 18 mins)1
Abbreviations:
AJCC, American Joint Committee on Cancer; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; ES SCLC, extensive stage small cell lung cancer; HCC, Hepatocellular carcinoma; IC, immune cell; IV, intravenous; LCEF, Lung Cancer Expert Forum; NSCLC, non small cell lung cancer; PD L1, programmed death ligand 1; SACT, systemic anti-cancer therapy; SC, subcutaneous; SCLC, Small cell lung cancer; TC, tumour cell; TNBC, Triple negative breast cancer; UICC, Union for International Cancer Control; UC, Urothelial carcinoma
References:
- TECENTRIQ SC Summary of Product Characteristics
- TECENTRIQ IV Summary of Product Characteristics
- Avelumab Summary of Product Characteristics.
- Durvalumab Summary of Product Characteristics.
- Burotto M et al. Ann Oncol 2023; 34(8): 693 702.
- Cappuzzo F et al. Primary results from IMscin002: A study to evaluate patient and healthcare professional-reported preferences for atezolizumab subcutaneous vs intravenous for the treatment of non-small cell lung cancer. Presented at ELCC, March 2024.